United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
What does it do?
United Therapeutics makes medicines for people with pulmonary arterial hypertension (PAH) — a serious condition where the arteries in the lungs become dangerously narrow, making the heart work extremely hard just to pump blood. Think of it like trying to force water through a kinked hose: eventually the pump burns out. Their drugs help relax those arteries so patients can breathe and move more normally. They also have an ambitious side project: growing human organs in pigs that could one day be transplanted into people.
PAH is a rare but deadly disease with no cure, which means patients need these drugs for life — giving United Therapeutics a reliable, recurring revenue base that most drug companies envy. Their newest inhaled drug, Tyvaso DPI, has been a breakout hit and is still growing fast, making this a rare specialty pharma company that is actually accelerating rather than fading. The organ transplant program, while years away from mainstream use, could be one of the most transformative medical technologies of the decade.
How does it make money?
United Therapeutics makes almost all of its money selling a family of drugs based on a molecule called treprostinil, all targeting PAH. Tyvaso DPI — an inhaled dry powder version — has become the star product and is driving most of the company's growth. Total revenue hit $3.2 billion in the latest year, up from $2.9 billion the prior year, and net income was a very healthy $1.3 billion, meaning they keep roughly 40 cents of profit for every dollar they earn. They sell primarily in the US, with some international exposure.
Why do investors care?
The growth story has two engines. First, Tyvaso DPI is still expanding its patient base, and there is a meaningful chunk of PAH patients who are not yet on any inhaled therapy — a gap United Therapeutics is actively closing. Second, their xenotransplantation program (using genetically modified pig organs for human transplants) is progressing through early clinical trials and, if it works, represents an entirely new multi-billion dollar business. For this to play out, Tyvaso DPI needs to hold off competition and the organ program needs to avoid major setbacks in trials.
Deep Dive
MemberA full investor briefing on United Therapeutics Corporation — history, leadership, risks, and outlook.